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ABSTRACT 
Premature infants are often plagued with respiration problems ranging from 
periodic breathing to apnea. These respiratory complications can be a result of 
underdeveloped respiratory organs, immaturity of the brainstem respiratory control 
center, genetic irregularities, or a combination of all three. This study sought to increase 
respiration with the administration of methylxanthines, which are respiratory stimulants, 
coupled with carbon dioxide (C02), also a respiratory stimulant. Neonatal rats aged 4 to 
7 days old were used to mimic premature infants' response to the interaction of 
methylxanthines and C02. Before beginning the respiratory studies, sections of a 4- and 
7-day-old rat brainstem were examined to compare the differences in development. The 
4-day-old rat brain had large folds (folia), while the 7-day-old rat brain lost those folds 
and was much denser in neuroglial and nerve cells. These differences show that as the rat 
matures, the brain also matures because the folds disappear, meaning that the brain is 
growing and new cells are synthesized as a part of this growth. After establishing this 
difference in brain development between the youngest and oldest rats, various doses of 
two different methylxanthines, theophylline (THEO) and 8-cyclopentyltheophylline 
(CPT), were injected into neonatal rats and paired with C02 percentages ranging from 1 
to 6%. The interaction of the drug and C02 was observed over a 45-minute period. Each 
rat was placed into a body plethysmograph that was connected by plastic tubing to a 
pneumotachograph to measure the rat's respiration. A control period of normal breathing 
for 5 minutes followed in order to establish a baseline respiration, which was followed by 
a C02 -response test involving exposure to increasing percentages of C02 from 1 to 6%, 
delivered at 2-minute intervals. This same procedure was repeated in 15-minute intervals 
until the 45-minute period concluded. C02 exposure produced a consistent increase in 
minute ventilation, tidal volume, and mean inspiratory flow, but not in respiratory rate, 
all of which were independent of the drug response. Although there was not an overall 
significant difference between doses ofTHEO, the highest dose, 40mg/kg, showed 
significant increases in minute ventilation, tidal volume, and mean inspiratory flow when 
paired with 5-6% C02. The dose of 10 mg/kg of THEO also showed increases in minute 
ventilation and tidal volume at higher C02 percentages. In contrast, CPT showed no 
significant increases in respiration at any dose. Interestingly, THEO doses were 
significant though CPT is the more potent form of the drug and has a higher affinity for 
adenosine A, receptors. In summary, C02 alone produced increases in minute ventilation, 
tidal volume, and mean inspiratory flow, and when paired with a dose of 40 mg/kg of 
THEO, these parameters increased further, showing that the highest doses ofTHEO 
paired with the highest doses of C02 produce a significant increase in respiration. 
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INTRODUCTION 
Preterm infants often suffer difficulties in respiration when they are first born due 
to immature brain and respiratory organ growth. The respiratory system begins forming 
from the ectoderm and mesoderm, with the organs developing during the fourth week of 
gestation (Crawford, 2011). The organs of the respiratory tract can be divided into two 
sections, conducting and respiratory (Crawford, 2011 ). The conducting section includes 
the nasal cavity, pharynx, larynx, trachea, bronchi, bronchioles, while the respiratory 
section includes the bronchioles, alveolar ducts, alveolar sacs, and alveoli (Crawford, 
2011). Premature infants can suffer many respiratory problems as a result of these organs 
not being developed fully while the baby is still in the womb (Crawford, 2011). Starting 
with the infant's relatively large head in comparison to its short neck, this relationship 
results in flexion, compromising the flow of air in the trachea (Brouillette et al., 1990; 
Crawford, 2011). In addition, nostril size can be small and become even smaller if 
blocked by mucus. Tongue size, being relatively large compared to the size of the infant 
mouth, also decreases breathing (Brouillette et al., 1990; Crawford, 2011 ). Both the 
larynx and the trachea are short and small, which means that a small obstruction can 
impair breathing (Brouillette et al., 1990; Crawford, 2011 ). The development of the ribs 
plays a significant role in breathing as well. Rib position is horizontal, and the thorax 
shape is circular (which changes to an ellipse later in development), and the chest wall is 
thin with little muscle to stabilize it (Crawford, 2011). In addition, the diaphragm is less 
efficient in contracting because of its flat shape (Crawford, 2011). Consequently, the 
cartilaginous rib cage becomes deformed easily, putting more stress on the diaphragm 
and chest wall muscles, which usually results in the chest wall collapsing and the 
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diaphragm being less sufficient in inspiration and expiration (Brouillette eta!., 1990). 
The chest deformity-occurs during REM sleep since the muscle activity is being inhibited 
(Brouillette et al. , 1990). 
In addition to the respiratory system, the brain plays a vital role in respiration. 
The medulla oblongata, a part of the brainstem located at the base of the brain where it 
thins into the spinal cord, is the regulation site for breathing, heart rate, and blood 
pressure, as well as minor functions such as mediating sensory impulses, endocrine 
secretions, and general awareness (Chiasson, 1988). The brainstem is arguably the 
simplest, but most important part ofthe vertebrate brain since in some animals (i.e. , 
lizards) it is the largest portion of their brain. Action potentials originating from neurons 
of the brainstem travel along the vagal and phrenic nerves (Leiter & St. John, 2004). 
These nerves show increased levels of activity when breathing is not normal, which 
shows evidence ofthe brain' s connection to respiration (Leiter & St. John, 2004). In 
particular, the phrenic nerve carries signals from the brainstem to the diaphragm, and the 
vagus nerve influences both respiratory rate and lung tidal volume by innervating the 
stretch receptors of the lungs (Akay, 2005). The information gathered from these nerves 
then travels back to the brainstem where a decision is made on how to optimize breathing 
(Akay, 2005). If the brainstem and nerves are underdeveloped, this process won' t be as 
efficient and the infant will struggle to breathe for a longer period of time. For instance, 
kittens born full term have 10% of vagal nerve fibers at birth and 50% about 60 days 
postnatal , and the diameter of these fibers continues to increase at a rate of 0.2 J..Lm/day 
after birth (Akay, 2005). If these kittens were born preterm, they would be less 
developed and most likely have more difficulty with respiration. 
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When infants are born pretenn, the respiratory organs and brain are 
underdeveloped causing breathing problems. One minor difficulty in respiration is 
known as periodic breathing, which is described as 3 or more pauses of more than 3 
seconds with less than 20 seconds between pauses (Oliveira et. al. , 2004; Brouillette et 
al., 1990). Normal pauses in infants breathing range from 6-10 seconds (Brouillette et 
al. , 1990). An even more serious condition is apnea, defined as pauses in breathing 
lasting 20 seconds or longer (Brouillette et al. , 1990). When paired with hypoxia, a 
deficiency in the amount of oxygen in the bloodstream, and bradycardia, a slow heart 
rate, apnea can be quite severe (Bleul et. al. , 201 0; Schmidt et. al., 2006). Primary apnea 
occurs when hypoxia is not treated by the stimulation of respiration (Bleul et. al., 201 0). 
Secondary apnea occurs if the condition worsens by neglecting treatment further, which 
leads to failure of the respiratory center in the brain and no oxygen supply to the brain, 
leading to risk of death (Bleul et. al., 201 0). There are three types of apnea including 
central apnea, where there is a cessation of respiratory effort for more than ten seconds; 
obstructive apnea, characterized by continued inspiratory efforts against an occluded 
airway; and mixed apnea, which is a combination of the first two types (Carley & 
Radulovacki, 2008). In any case, if these diseases are not treated, serious complications 
or even death may result. 
One type of preliminary treatment is the administration of carbon dioxide (C02) 
to those suffering from apnea. Carbon dioxide naturally causes infants to increase their 
minute ventilation and tidal volume, due to its respiratory stimulating effect, but C02 
alone can only do so much when the infant is pretenn. One group of investigators 
hypothesized that a decreased sensitivity to C02 correlates with younger age, which 
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makes sense since the younger the infant is, the less developed the breathing organs and 
brain function are (Rigatto et. a!., 1975). This hypothesis was supported by the C02 
response curve slope, which increased by 42% from 32 to 37 weeks gestation and 62% 
from 2 to 27 days of age (Rigatto et. a!, 1975). These findings support the idea that as the 
infant ages, its respiratory center in the brain as well as its respiratory organs mature and 
become more sensitized to C02. The increased sensitivity to C02 results in a greater 
response to C02, which also facilitates more consistent and deeper breathing (Rigatto et. 
a!., 1975). This study stimulates questions about whether this sensitivity to C02 seen in 
infants can be manipulated and enhanced if paired with other treatment options. 
One option that could enhance C02 effects would be coupling its use with 
methylxanthine drugs that act as respiratory stimulants by antagonizing adenosine A 1 and 
A2 receptors. Adenosine acts as a neurotransmitter with numerous biological actions, 
including respiratory depression (Mokry & Mokra, 2013; Shamin, 1989). An 
overactivity of central adenosine mechanisms is linked to irregular breathing or apnea in 
premature infants (Mokry & Mokra, 2013). By administering methylxanthines, the A 1 
and A2 receptors are bound to the drug and thus cannot continue on their normal path of 
bronchoconstriction (Mokry & Mokra, 2013; Brunton et.al., 2006; Shamin, 1989). The 
xanthine drugs widen the bronchi, relax airway smooth muscle, and enhance breathing 
(Brunton et.al., 2006). Theophylline (THEO) is a methylxanthine that is often used to 
treat preterm infants with ventilatory problems. However, this drug can be even more 
effective in treatment by the addition of different substituents to the 1, 3, and 8 positions 
of the xanthine nucleus, which would increase the potency (Shamin, 1989). However, 
additions greater than propyl at the 1 and 3 positions reduce activity at both adenosine A 1 
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and A2 receptors (Shamin, 1989). By adding cycloalkyl groups to the 8 position of 
THEO, the potency increases, while it increases the activity at adenosine A1 receptors 
with only a small increase in activity at adenosine A2 receptors (Shamin, 1989). Thus 8-
cycloalkyl moieties are potent and selective for adenosine A 1 receptors. The difference 
between the drug's ability to inhibit A1 and A2 receptors could be because there are many 
subclasses in each receptor and this range of subclasses has many different recognition 
sites for the drug to bind to (Shamin, 1989). In contrast to 8-cyclopentyltheophylline 
(CPT), administration ofTHEO requires a higher dose, which often puts the infant at 
higher risk for negative side effects such as increased heart rate, irritability, seizures, and 
vomiting. This increased activity of the heart and central nervous system will cause the 
infant to bum more calories and use more energy, while the gastrointestinal distress will 
interfere with nutrition (Brunton et. a!., 2006; Aranda et. a!., 1986; Brouillette et. a!., 
1990). THEO is bound to plasma proteins to a greater extent than is caffeine (another 
common xanthine derivative), and the fraction bound declines as the concentration of 
methylxanthine increases, which explains why a larger dose of theophylline is needed 
(Brunton et. al., 2006). Caffeine is another drug option for the treatment of neonatal 
apnea and has similar effects to THEO and CPT (Brunton et. a!., 2006). 
Aranda et. a!. (1986) found that when methylxanthines were used in conjunction 
with additional COz, there were increases in ventilation, tidal volume, and ventilatory 
response to C02. In addition, Uauy et. a!. (1975) found that THEO increased minute 
volume and sensitivity of the central response to hypercapnia (elevated C02). Both of 
these studies provide concrete evidence that has led to my hypotheses. In order to mimic 
the interaction ofTHEO and CPT with the ventilatory response to C02 seen in preterm 
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infants, newborn rats were chosen because they serve as a good model for breathing 
control of premature infants with a diminished respiratory response to C02. Rigatto et. al. 
(1981) explains that rats and humans share similar basic physiology, similar organs, 
similar body plans, and control body chemistry by secreting hormones, which make the 
infant rat a satisfactory substitute for premature infants. With that in mind, my 
hypotheses include: (1) the administration of methylxanthines such as THEO and CPT 
will increase the newborn rat's ability to respond to C02, which in tum will increases 
respiration; (2) CPT will show a more significant effect on respiration than THEO since it 
is the more potent methylxanthine at adenosine A 1 receptors; (3) C02 alone will also 
increase respiration, but not as significantly as when paired with a methylxanthine. 
These comparisons will help to identify benefits of both THEO and CPT, as well as 
effective and safe doses of each drug. My overall research goals are to further the 
understanding of the effects ofmethylxanthines on respiration and to identify a safe, 
effective respiratory stimulant drug that can help treat infant apnea. 
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METHODS 
Animals 
The subjects used for this experiment were newborn rat pups obtained from a 
breeding colony of Sprague-Dawley laboratory rats at Eastern Illinois University in 
Charleston, Illinois. The colony was kept in a temperature controlled building within a 
separate air filtering system. The newborn rats were selected randomly within the desired 
ages ranging from 4 to 7 days old because this age mimics the level of respiratory control 
of a preterm infant (Albers & McGilliard, 2012). When the rat was chosen the body 
weight, sex, age, and litter number were recorded. 
Administration of Drugs and Carbon Dioxide 
Respiration studies were performed on 4- to 7-day-old rats with three different 
variables available including two drugs (CPT and THEO) and C02• The studies were 
separated according to drug, with the CPT studies done first and the THEO studies done 
after. Both studies included three doses of a methylxanthine and increasing percentages 
of C02 paired with each dose. Each rat served as its own control, but there were also two 
saline control groups that received 0.9% sodium chloride instead of the drug and were 
exposed to C02 in the same manner as the drug-treated rats. Each treatment group 
consisted of8 rats with a total of64 animals (16 control (saline) rats, 24 THEO-injected 
rats, and 24 CPT-injected rats). Carbon dioxide levels ranged from 1% to 6% with the 
percentage increasing by one every 2 minutes. CPT doses started at a low dose of 320 
~-tglkg and continued to 640 1-tg/kg, and 1280 1-tg/kg. THEO doses were administered at 
1 0 mg/kg, 20 mg/kg, and 40 mg/kg. These doses were chosen because previous studies 
in this lab established the dose range of THEO and CPT that produced respiratory 
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stimulation in newborn rats (Albers & McGilliard, 2012). The methylxanthines are 
poorly soluble in water and CPT has especially low water solubility (Shamin, 1989). 
Therefore, each drug was dissolved in a small amount of 1.0M NaOH and then diluted to 
the final concentration with 0.9% NaCl (with the pH being adjusted to about 8 in the 
process). The concentration was such that the drug could be administered in a volume of 
5 J.tl/g body weight (e.g. 10 mg/kg rats were injected with a THEO concentration of 2 
mg/ml). Because CPT was at the limit of its solubility, the highest dose (1280 J..Lg/kg) 
was given as 10 J..Lllg of 128 J..Lg/ml. 
Animal Preparation and Equipment Used 
After the doses of each drug were made, the animal was prepared. A rat was 
randomly chosen from the litter, where it was sexed and weighed. The animal was 
placed in a plethysmograph, which is a cylindrical container 8 em long and 2.6 em in 
diameter that confines the rat with a rubber seal around its neck and directs flow of 
displaced air through an outlet for measurement. The plethysmograph was placed in an 
environment stabilizing apparatus that consisted of a 6.5 em internal diameter water-
jacked cylinder that was heated to 35°C to maintain the animal ' s body temperature and 
sealed with rubber stoppers on both ends to control C02 concentration to which the rat 
was exposed (Fig. 1 ). The plethysmograph was connected to a Fleisch #0000 flow 
transducer (Phipps+Bird, Richmond, VA) by plastic tubing. This device, paired with a 
differential pressure transducer and carrier demodulator (Validyne Engineering, 
Northridge, CA) served as a pneumatotachograph, measuring the flow of air moving into 
and out of the cylinder as the rat breathed. Another plastic tube connected the 
environment stabilizing apparatus to the gas mixing apparatus, which consisted of a tank 
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of 8% C02, an air compressor (GAST, Benton Harbor, MI), a Model 252 airway gas 
monitor (Puritan-Bennett, Wilmington, MA), and a gas mixer (Matheson Gas Products, 
Basking Ridge, NJ) . The gas mixer was operated by hand to control the percentage of 
C02. These values were measured on the airway gas monitor in percentages, with the 
standard oxygen percentage being between 18-21% and the C02 percentage ranging 
from 0-6%. Before studies began, the pneumotachograph was calibrated by plunging air 
from a 20 ml calibration syringe through the flow transducer to see if the correct amount 
of air was being measured. 
Respiratory Studies 
After equipment calibration and drug doses were prepared, each rat was put 
through a preliminary control phase (without any drug) consisting of a baseline 
respiration, which was tested for 5 minutes followed by 2-minute intervals where the C02 
percentage was increased by 1% increments in a range of 1-6%. Then, each rat was 
injected subcutaneously through the scalp with a drug (either CPT, THEO, or saline) 
without removing the rat from the plethysmograph. After that, another 5-minute baseline 
was administered, followed by 3 rounds of 2-minute intervals where the C02 percentage 
was increased again in a range from 1-6%. An injection was used as opposed to a 
capsule because the infant rat's digestive system isn' t developed enough to metabolize a 
capsule, and the drug would take longer to be absorbed and affect the rat' s respiration. In 
addition, the injection was given subcutaneously on the scalp because it was the most 
accessible region, while the rat was in the apparatus, and this location provided low risk 
of injury to vital organs. Respiratory rate and volume were recorded continuously, which 
was roughly every 15 minutes (the study stops at 45 minutes) . The data collected were 
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transferred to a PowerLab. The measurements taken from the PowerLab included the 
respiratory rate (f), the tidal volume (VT), minute ventilation (V 6), time of inspiration 
(TI), time of expiration (T E), and mean inspiratory flow (MIF; VT/TJ). Upon completion 
of each experiment, the rat was returned to its mother. 
Data were expressed as both raw averages and percent change compared to the 
rat's mean pre-drug control measurement, and C02-response curves were drawn for each 
drug dose. Percent change is valuable because respiratory data in unanesthetized animals 
are highly variable, and this removes the predrug variability in respiration between 
animals. In addition, the graphs were compiled by separating THEO and CPT, as well as 
separating the time intervals (control period, 15 minutes, 30 minutes, and 45 minutes 
after treatment added). 
Treatment effects and C02 response were compared by two-way analysis of 
variance with repeated measures. Separate statistical analyses were conducted on each 
drug and each respiratory variable (e.g. THEO V6). Each analysis included the range of 
C02 concentrations tested (0 to 6%) and times (predrug to 45 min postdrug). Statistical 
significance was determined at the a= 0.05 level by two-way analysis of variance 
(ANOV A) with repeated measures since each rat served as its own control (Steel and 
Torrie, 1980). Multiple comparisons (e.g. comparisons between doses) were made using 
the Holm-Sidak method (GraphPad Software, 2014). The analysis of variance was 
performed using SigmaPlot 11.2 (Systat Software). 
Rat Brainstem Dissection Technique 
Four and seven-day-old rats were euthanized by exposure to C02 prior to 
dissection. Skin on the rat's scalp was removed immediately afterward using scissors, 
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and then the skull was cut from the base using scissors. This exposed the cerebellum and 
brainstem fully. The brainstem was removed and fixed in formalin-acetic acid-alcohol 
(FAA) for two days. 
Rat Brainstem Histology 
After fixing in FAA, the brainstem was transferred to a scintillation vial where it 
was washed in tap water and dehydrated in four changes of 70% ethanol for 1 hr each. 
The specimen went through more dehydration steps, containing five solutions with 
varying amounts oft-butyl alcohol (Table 1). The specimen remained in solution I for 12 
hrs and solutions II-IV for 6 hrs each. The specimen went through three changes of 
solution V (pure t-butyl alcohol), where two changes were for 6 hrs each and one change 
was for 12 hrs. A small amount of eosin Y was added to the first change of solution V to 
stain the parts of the specimen that were transparent. Lastly, the specimen was placed in 
a 50:50 mixture oft-butyl alcohol and paraffin oil for 1 hr. Specimen were the 
transferred to paraffin, cast, and mounted onto blocks for sectioning (Ruzin, 1999). 
Sections were made on a rotary microtome at 10 pm thickness (Ruzin, 1999). Ribbons 
were mounted onto slides using Haupt's adhesive (Ruzin, 1999). To remove the paraffin, 
sections were put through two changes of limonene for 5 minutes each. Rehydration was 
done using a graded series of ethanol. Sections were stained in Heidenhem' s ironalum 
hematoxylin and then was placed in a solution ofDI water with two drops of ammonia 
for 5 minutes and rinsed in DI water for 5 minutes (Guyer, 1936). Eosin was used as a 
counterstain for 20 minutes (Guyer, 1936). 
Stained sections were dehydrated in graded ethanol series and cleared in 
limonene. Permount was used to attach the coverslip. Slides were examined with a light 
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microscope to compare the morphological differences between the brainstems of 4- and 
7 -day-old rats. 
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RESULTS 
Respiration Studies 
The trend for THEO studies showed a significant increase in V E when 10 mg/kg 
and 40mg/kg ofTHEO were used when compared to the time and percent C02 (Fig. 2), 
while all treatments for CPT showed similar results whether in the control period or 
anytime after the treatment was added (Fig. 3). Looking first at V E, there was no 
significant treatment effect for THEO (p=0.529, two-way ANOV A with repeated 
measures). However, there was a highly significant effect of time and% C02 (p<0.001), 
and there was a highly significant interaction between treatment (dose), time, and% C02 
(p=0.004) (Table 2). 
When multiple comparisons were made between doses of THEO and saline at 
different times and% C02 by the Holm-Sidak method, 10mg/kg ofTHEO produced an 
increased VE compared to saline at 30 and 45 minutes at 6% C02 (p=0.038 and 0.004, 
respectively), and 40mg/kg of theophylline also increased V E at 45 minutes at 6% 
(p=0.008). 
Similar to THEO, CPT had no significant treatment effect (p=0.166, two-way 
ANOVA with repeated measures) . However, there was a highly significant effect of time 
and% C02 (p<0.001), while there was no significant interaction between treatment 
(dose) and time and% C02 (p=0.703) (Table 3). Although no treatments of CPT were 
significant, there were some instances of treatments causing increases in V E· For 
instance, 320 11g/kg of CPT increased V Eat 15 minutes and 3 and 5% C02 (p=0.05 and 
0.010, respectively), 1280 11g/kg of CPT increased VE at 15 minutes at 6% (p=0.047), and 
640 11g/kg of CPT increased V Eat 15 minutes at 6% (p=0.025) and 45 minutes at 6% 
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(p=0.028). There was a significant increase in V E as more C02 was added and the time 
increased (p<O.OOl). It should be noted that any significant difference between any 
parameter and increased time and C02 represents the normal C02 response curve. 
No treatments ofTHEO or CPT produced significant changes in f. Looking at 
THEO, there was no significant treatment effect in f (p=0.350), time and % C02 
(p=0.092) and treatment interaction with time and percent C02 (p=0.178) (Fig. 4, Table 
4). Similarly, CPT results for f showed no significant treatment effect (p=0.943). 
However, there was a highly significant effect of time and% C02 (p<O.OOl), while there 
was no significant interaction between treatment (dose) and time and% C02 (p=0.548) 
(Fig. 5, Table 5). 
Tidal volume (VT) showed a significant treatment effect for THEO at 40mg/kg 
(p=0.006) and a highly significant effect oftime and% C02 (p<0.001), while there was 
no significant interaction between treatment (dose) and time and% C02 (p=0.263) (Table 
6, Fig. 6). When multiple comparisons were made between doses ofTHEO and saline at 
different times and% C02 by the Holm-Sidak method, 40 mg/kg ofTHEO showed 
increased VT at 15 minutes at 5 and 6% (p=0.003 and p<0.001 respectively), 30 minutes 
at 6% (p<O.OOl), and at 45 minutes at 2,3 ,5,and 6% (p=0.009, 0.015, 0.002, 0.001). In 
addition, 20 mg/kg ofTHEO showed some increases in VT at 45 minutes at 2% and 5% 
(p=0.004, 0.033), but the treatment didn't produce an overall significant difference from 
saline. 
In contrast, CPT treatments had similar VT's and showed no significant 
differences in treatment (Fig. 7). There was no significant treatment effect for CPT 
(p=0.840). However, there was a highly significant effect oftime and% C02 (p<0.001), 
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while there was no significant interaction between treatment (dose) and time and% C02 
(p=0.374) (Table 7). 
Time of inspiration (TI) had no significant variance between THEO treatments 
(Fig. 8) and CPT treatments (Fig. 9). Time of expiration (T E) also did not show any 
significant variance (Fig. 10, Fig. 11 ). Starting with the THEO treatments, there was no 
significant treatment effect for T1 (p=0.783). However, there was a highly significant 
effect of time and% C02 (p<0.001), while there was no significant interaction between 
treatment (dose) and time and% C02 (p=0.794) (Table 8). In addition, there was no 
significant treatment effect forTE (p=0.567). Similar toT~, there was a highly significant 
effect of time and % C02 (p<O.OO 1 ), but no significant interaction between treatment 
(dose) and time and% C02 (p=O.l65) (Table 10). The CPT treatments shared similar 
results, with no significant treatment effect for T1 (p=0.499). However, there was a 
highly significant effect oftime and% C02 (p<0.001), but no significant interaction 
between treatment (dose) and time and% C02 (p=0.826) (Table 9). Lastly, there was no 
significant treatment effect forTE (p=0.882). There was a highly significant effect of 
time and% C02 (p<O.OOl) but no significant interaction between treatment (dose) and 
time and % C02 (p=0.125) (Table 11 ). 
Similarly, MIF resulted in the same significance trend between time and C02 for 
both THEO and CPT treatments (p<0.001). Looking at THEO, there was no significant 
treatment effect for MIF (p=0.270) and slightly significant interaction between treatment 
(dose) and time and% C02 (p=0.026) (Table 12). When multiple comparisons were 
made between doses ofTHEO and saline at different times and% C02 by the Holm-
Sidak method, 40mg/kg ofTHEO increased MIF at 15 minutes at 5 and 6% C02 
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(p=0.006,0.018), 30 minutes at 5 and 6% C02 (p=0.005, 0.026), and 45 minutes at 6% 
C02 (p=0.026) (Fig. 12). 
CPT studies did not show a difference between treatments (Fig. 13). There was 
no significant treatment effect (p=0.879). However, there was a highly significant effect 
oftime and% C02 (p<0.001) but no significant interaction between treatment (dose) and 
time and % C02 (p=0.905) (Table 13). A summary of all p-values for each treatment is 
listed for comparison (Table 14). 
Raw values for both THEO and CPT had no significant differences in treatment 
forVE, f, VT, T~, TE, and MIF (Figs. 14-25). 
Brainstem Histology 
When comparing the brainstems of the 4-day-old rat to the 7-day-old rat, there are 
two distinct differences. The younger, 4-day-old rat brain section contained more folds 
within the brain and had less nerve and neuroglial cells (Fig. 26). In contrast, the older, 
7-day-old rat brain section had lost those folds (Fig. 27) and gained more numerous nerve 
and neuroglial cells (Figs. 28-30). 
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DISCUSSION 
Respiration Studies 
Theophylline studies revealed that 40mg/kg was the drug dose with the most 
reactivity, as shown by its significant increases in V E, V T, and MIF (Tables 2, 6, 12). 
These increases in VE, VT, and MIF are all consistent with a similar study by Bleul et. al. 
(20 1 0) involving neonatal calves. They were given injections of THEO with the 
intention of maintaining regular respiration, improving oxygen uptake, and carbon 
dioxide release. Although it took over an hour to show increases in respiration, the 
effects were observed. The long wait-time could have been because they used a low dose 
ofTHEO. In my study, the highest dose ofTHEO was effective, but only at the highest 
concentrations of inhaled of C02. For instance, 40mg/kg ofTHEO was only reactive at 
high C02 percentages (5-6%), but did not show a significant trend in time after injection 
ofthe drug since there were increases in V6, VT, and MIF at 15 minutes, 30 minutes, and 
45 minutes (Figs. 2, 6, 12). The other, lower doses ofTHEO (10, 20 mg/kg) did not 
result in increases in these parameters (V 6, V T, and MIF), so using those doses would not 
be recommended, even though they showed signs of significance at certain times. 
Another study by Milic-Emili & Grunstein (1976) supports the results from this study 
that found that respiration (V E and V T) increased at higher C02 percentages. They 
experimented with different levels of C02 on cat respiration and found that increasing the 
amount of C02 into the body, increases respiration, specifically V 6 and VT (C02 response 
curve). 
The other parameters, T 1 and T 6, did not increase when any dose of THEO was 
added (Figs, 8 and 1 0), and no significant C02 response trend existed for respiration rate 
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(Fig. 4). My results supported the previous work by Bleul et. al. (201 0) and Rigatto et. 
al. (1988), where they found that breathing rate (f) remained constant no matter what 
treatment was added. T1 and T E did have significant C02 response curves with T1 
increasing while T E decreased, but there was no effect of THEO treatment, which is 
logical since the breathing rate had no pattern. 
In addition to THEO, CPT is considered a more efficient alternative due to its 
increased potency and affinity for adenosine A 1 receptors. CPT is developed by the 
addition of a cycloalkyl group to the 8 position of theophylline. This small change allows 
CPT to be given at a much lower dose than THEO, while exhibiting the same effects of 
increased depth and consistency of respiration and lowering the risk ofharmful side 
effects that higher doses can cause (Shamin 1988). Previous studies on the effects of 
CPT on respiration in neonatal rats by Albers & McGilliard (2012) showed that 640 
Jlg/kg and 1280 Jlg/kg CPT significantly increased respiratory parameters including V E, 
VT, and MIF. These doses, although high for CPT, are in micrograms, while an 
equivalent dose ofTHEO would have to be in milligrams to have any significant effect, 
which supports the idea of CPT being a more potent and efficient drug than THEO. 
However, in my study, CPT had no doses that were significantly different from 
saline, which is surprising since we expected CPT be more potent than THEO. 
Specifically, CPT has a higher affinity for A 1 and A2 receptors than THEO, which means 
that it should more easily bind to these receptors. One reason for CPT's ineffectiveness 
in my study could be the doses administered. The 3 doses of CPT (320 Jlg/kg, 640 Jlg/kg, 
and 1280 Jlg/kg) were much smaller than the THEO doses (1 0 mg/kg, 20 mg/kg, 40 
mg/kg), and rightfully so since they should have an increased potency, but even then, the 
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CPT dose could be larger. One problem with increasing the dose is that solubility is 
extremely low. Other solvents have to be explored to keep the drug in solution. At the 
doses tested, the null hypothesis could not be rejected, despite previous work showing 
that 640 ug/kg, and 1280 ug/kg CPT produced significant increases in respiration (Albers 
& McGilliard, 2012). For future studies it would be important to insure the drug being 
used is new and made correctly, as well as increasing the dose of CPT. If solubility were 
a problem, the solvent could be changed to allow delivery of higher doses. A higher dose 
could also be produced through intravenous infusion of CPT, but this would be 
technically very difficult in a newborn rat. 
When comparing THEO to CPT, THEO is the apparent choice to increase 
respiration in neonates because it was the only drug to show any significant increase in 
the respiratory parameters. This is consistent with other studies claiming that 
theophylline remains a widely used drug to treat neonates. Durand et.al. (1987) used 
THEO paired with C02 to wean premature infants off of a ventilator. They found that 
treatment with THEO benefitted respiration without a ventilator by increasing 
bronchodilation and increasing diaphragm contractility. Specifically, compared to 
control infants, those given THEO were on the breathing machine for less time, did not 
require reintubation, and had overall more consistent breathing patterns. 
Brainstem Histology 
These observations of increased respiration with the administration of 
methylxanthines paired with C02 are effective in preterm infants. These drugs are 
required because the brain (along with respiratory organs) are not as developed in the 
younger infant. In a dissection of a 4 and 7 -day-old rat brain, there was a visible 
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difference in brain development. The 4-day-old rat brain had large folds or folia, while 
the 7-day-old rat brain lost those folds and was much denser in neuroglial and nerve cells. 
These differences in the two brains are plausible since as the rat matures, the brain also 
matures (Snider et. a/.1950; Casey et. al. 2005). The folds disappear as the brain grows, 
and the new cells are synthesized as a part of this growth and development as well 
(Snider et. a/.1950; Casey et. al. 2005). Although age relationships weren't defined for 
this study, it is still important to note the apparent growth of the brain in just four days 
and how this growth along with treatment ofTHEO/CPT and C02 significantly increases 
respiration. 
Other possibilities for future studies would be to observe long-term effects of 
methylxanthines like THEO and CPT. The use of caffeine (1, 3, 7-trimethylxanthine) in 
preterm infants has shown that, in the short term, the rate of bronchopulmonary dysplasia, 
which is defined as the need for supplemental oxygen after 36 weeks of living is reduced 
(Schmidt et. al. 2006). In addition, infant reliance on supplemental oxygen from 
respirators was greatly reduced (Schmidt et. al. 2007). In the long term, methylxanthines 
showed reduced neurodevelopmental disabilities such as cerebral palsy, cognitive delay, 
and hearing loss (Schmidt et. al. 2012). Similarly, methylxanthines have been shown to 
reduce an infant's ability to gain weight in the first two weeks of treatment, but following 
this short weight loss, weight gain continues normally (Schmidt et. al. 2006). 
22 
CONCLUSIONS 
Premature infants plagued with respiration problems like periodic breathing and 
apnea can be treated with respiratory stimulants like THEO and CPT coupled with C02. 
Although there was not an overall significant difference between doses ofTHEO, the 
highest dose, 40mg/kg, showed significant increases in minute ventilation, tidal volume, 
and mean inspiratory flow when paired with 5-6% C02. The dose of 10 mg/kg ofTHEO 
also showed increases in minute ventilation and tidal volume at the higher C02 
percentages. In contrast, CPT showed no significant increases in respiration at any dose. 
For both CPT and THEO, C02 exposure produced a consistent increase in minute 
ventilation, tidal volume, and mean inspiratory flow, but not in respiratory rate all of 
which were independent ofthe drug response. Consequently, C02 alone produced 
increases in minute ventilation, tidal volume, and mean inspiratory flow, and when paired 
with a dose of 40 mg/kg of THEO, these parameters increased further showing that the 
highest doses of THEO paired with the highest doses of C02 produce a significant 
increase in respiration. From my findings, I would suggest that preterm infants suffering 
from respiration problems should be put on THEO paired with 5% C02. Although 
further experimentation should be done with similar drugs and different entry routes into 
the body, THEO would be a good treatment to aid a premature infant with breathing 
problems. 
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Fig. 18. The effect ofT
H
E
O
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n
 the a
v
e
rage tidal v
olum
e response to C
0
2 at four different tim
e periods
,
 predrug (A)
,
 15 m
in (B)
,
 30 
m
in (C), a
nd 45 m
in (D) after drug injection 
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Fig. 19. The effect of C
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 the av
erage tidal v
olum
e response to C
0
2 at four different tim
e periods, predrug (A)
,
 15 m
in (B)
,
 30 m
in 
(C), and 45 m
in (D) after drug injection 
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Fig
.
 20. The effect ofT
H
E
O
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 the av
erage tim
e of inspiration re
sponse to C
0
2 at four different tim
e periods
,
 predrug (A)
,
 15 m
in 
(B), 30 m
in (C), a
nd 45 m
in (D) after drug injection 
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 the a
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e
a
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 response to C
0
2 at four different tim
e periods, predrug (A), 15 m
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Fig. 25. The effect of C
PT o
n
 the av
erage m
e
a
n
 inspiratory flow
 response to C
0
2 at four different tim
e periods
,
 predrug (A)
,
 15 m
in 
(B)
,
 30 m
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,
 and 45 m
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57 
Fig. 26. Section of a four-day-old w
hite rat (Rattus n
o
rvegicus) 
brainstem
 (scale set at 100 J.tm). 
Fig. 27. Section of a 7-day-old w
hite rat (Rattus n
o
rv
egicu
s) 
brainstem
 (scale set at 100 J.tm). 
58 
Fig. 29. Section of a 4-day-old rat (Rattus n
o
rvegicus) 
brainstem
 (scale set at 50 Jlm). 
Fig. 30. Section of a 7-day-old rat (Rattus n
o
rvegicus) brainstem
 
(scale set at 50 Jlm). 
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